(Q44356027)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

Hormone Replacement Therapy

1 November 2019

main subject

Sweden

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

Christian Ingvar

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Anna Bladström

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

English

0 references

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

1387-1392

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12627501%20AND%20SRC:MED&resulttype=core&format=json

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

A population-based cohort study of HRT use and breast cancer in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Menopausal oestrogens and breast cancer risk: an expanded case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Agreement between interview information and physician records on history of menopausal estrogen use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Postmenopausal hormone therapy and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

7 January 2021

Prognostic characteristics in breast cancers after hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

7 January 2021

Low biologic aggressiveness in breast cancer in women using hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

7 January 2021

Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

7 January 2021

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11205

7 January 2021